Amyloid pathology in the diagnosis and treatment of cognitive decline and dementia in patients with Down syndrome.

• Conditions: cognitive decline; dementia; 10057167

• Registration Number: NL-OMON30898
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 384

Inclusion Criteria

- Down syndrome
- Participation with previous research of the collaborator of this study (Dr A. Coppus) because this proposal can be viewed as the successor of the previous work of Dr. Coppus and because some baseline determinants are important risk factors for our outcome.

Exclusion Criteria

Dementia at the baseline study

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>incidence of dementia (number of incident case per 100 persons year)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- change in cognitive performance (follow-up minus baseline).<br /><br>- difference in serum amyloid between those that have or have not developed<br /><br>dementia.<br /><br>- difference in radiological characteristics between those that have or have<br /><br>not developed dementia.</p><br>